Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
Guidance Documents/Guidance-Document/Benefit-Risk Assessment for New Drug and Biological Products

Benefit-Risk Assessment for New Drug and Biological Products

Detailed guidance document from FDA and regulatory agencies.

Document Details

Guidance Document

October 17, 2023

August 10, 2024

Center for Drug Evaluation and Research

90bf84f4-05cf-4617-b13d-bbb345349aed

Related Documents

Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry: Guidance for Industry

Guidance DocumentJune 22, 2023Center for Drug Evaluation and Research
View Details →

Identification of Medicinal Products — Implementation and Use

Guidance DocumentMarch 30, 2023Center for Drug Evaluation and Research
View Details →

Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry

Guidance DocumentMarch 1, 2023Center for Drug Evaluation and Research
View Details →

Quick Actions

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.

KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.